[ad_1]
“To date, there is no evidence that BioNTech’s current COVID-19 vaccine needs to be adapted due to major [virus] varieties, “the company said in a statement.
However, in preparation for the need to adjust the existing vaccine at some point, the company began testing a “modified and varied” version of the vaccine in March.
“The purpose of this study is to study the maintenance path that BioNTech and Pfizer would take if [virusas] SARS-CoV-2 would change enough to require a renewed vaccine, ”the company said.
The effect of a possible third dose of the vaccine on prolonging immunity and protection against COVID-19 virus strains is also being evaluated.
BioNTech chief Ugur Sahin said in April that the company’s vaccine protects against a strain of the virus found in India.
The BioNTech and Pfizer vaccine was first approved in the West and is now available in more than 90 countries around the world.
The company expects to expand production and produce up to 3 billion by the end of the year. vaccine dose. Previously it was planned to produce 2.5 billion. dose.
